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Objective: To determine the association between long chain omega-3 polyunsaturated fatty 
acid (n-3 PUFA) supplements intake and cognitive decline in an older Chinese population. 
Methods: Prospective cohort study of 1,475 community-dwelling elderly Chinese. Omega-3 
PUFA supplements intake and Mini-Mental State Examination (MMSE) were assessed at 
baseline. MMSE was re-assessed at a median of 1.5 years after baseline and cognitive 
decline was defined as at least 2-points drop in MMSE score from baseline to follow-up. 
Odds ratios (ORs) of association between n3-PUFA supplements intake and cognitive decline 
were calculated in logistic regression models controlling for baseline confounding variables. 
Results: Daily n-3 PUFA supplements intake was significantly (p=0.024) associated with 
lower risk of cognitive decline (OR=0.37, 95% C.I. 0.16-0.87) after controlling for age, 
gender, education, number of medical comorbidity, the presence of vascular risk 
factors/diseases, smoking, alcohol drinking, depression, APOE ε4 allele carrier status,  
nutritional status, level of leisure activities, baseline MMSE and length of follow-up. The 
association remained significant (p=0.015) after excluding participants with baseline 
cognitive impairment (MMSE<24), diabetes, stroke, and cardiac diseases (OR=0.23, 95% C.I. 
0.07-0.75). No statistically significant association (OR=1.02, 95% C.I. 0.81-1.27) of fish 
consumption with cognitive decline was found.  
Conclusion: Daily n-3 PUFA supplements consumption was independently associated with 
less cognitive decline in elderly Chinese.  




 The potential benefits of long chain omega-3 polyunsaturated fatty acids (n-3 
PUFAs), primarily eicosapentaenoic acid (EPA, C20:5n-3) and docosahexaenoic acid (DHA, 
C22:6n-3), in slowing cognitive decline in non-demented individuals or reducing the risks of 
dementia is of great scientific and public health interest. Biological data suggest that both 
EPA and DHA could reduce cardiovascular risks and improve cerebral blood flow, reduce 
inflammation, as well as directly limit the progression of Alzheimer’s disease (AD) pathology 
(Fotuhi et al., 2009). 
  
 To date, the results from eleven observational studies and four randomized 
controlled trials have been inconsistent or inconclusive, possibly due to methodological 
differences in measurements and unaccounted sources of n3-PUFA. Measurements of n-3 
PUFA were made using dietary consumption of fish in five observational studies, total 
dietary n-3 PUFA in three observational studies, plasma, serum or red blood cell n-3 PUFA in 
three observational studies. In the Autopen Elderly Study, a significant association with 
cognitive decline was not observed at 3-year follow-up (Kalmijn et al., 1997) when only fish 
consumption was measured, but a subsequent analysis which included other dietary sources 
of n-3 PUFA and with 5-year follow-up (van Gelder et al., 2007) found a positive association. 
On the other hand, the Chicago Health and Aging Project showed that fish consumption but 
not the intake of n-3 PUFA (from different food items) was associated with less cognitive 
decline (Morris et al., 2003). The use of supplements is a distinct source of n-3 PUFA but 
there are no published observational studies on its association with cognitive decline, 
because the use of these supplements was considered to be very low in the general 
population (Morris et al., 2006). 
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   In the present study, we aimed to determine the association between omega-3 
polyunsaturated fatty acid (n3-PUFA) supplements intake and cognitive decline in a large 




 The Singapore Longitudinal Aging Studies (SLAS) is a prospective cohort study of 
elderly Singaporeans living in a geographically defined area in South East Region of 
Singapore. The sample methodology has been described in detail previously (Ng et al., 
2008). Briefly, a total of 2808 eligible residents (78.2% response rate) were identified 
through door-to-door census and agreed to participate. Residents who were physically or 
mentally incapacitated to give informed consent or participate were excluded. Extensive 
face-to-face interviews, assessments and tests were conducted by trained research nurses 
in the on-site study centre. At enrolment, 2607 Chinese participants were interviewed in the 
2004/2005 baseline examination. In 2005/2006, 1673 Chinese participants completed first 
follow-up examinations. After excluding participants with missing data on omega-3 intake 
(N=10) and participants with probable dementia (CDR global score ≥ 0.5 or IQCODE score 
≥3.4, N=188), we studied a final cohort of 1475 non-demented Chinese participants, who 
completed baseline and follow-up assessment (median=18 months after baseline). 
 
2.2 Cognitive function 
 Cognitive performance was assessed by the locally validated Chinese version of the 
MMSE (Ng et al., 2007). Cognitive impairment was defined by an MMSE total score of 23 or 
less, which was previously shown to have high sensitivity (95.5%) and specificity (83.5%) for 
 5 
predicting dementia in older Singaporean Chinese adults. Cognitive decline was defined as 
at least 2-point drop in the MMSE scores between baseline and follow-up assessments 
(Kalmijn et al., 1996). 
 
2.3 Omega-3 PUFA intake 
 Information on the habitual intake of n-3 PUFA supplements was determined using a 
self-reported single question, “For the past 12 months, do you regularly consume the 
following health supplements: omega-3?” The responses were measured on a 5-point Likert 
scale. Because the responses were extremely bimodal in their distribution, with less than 5% 
in the intermediate frequencies of intake, they were categorized into daily and non-daily 
consumptions. Respondents were considered to be daily consumers of n-3 PUFA if they 
reported daily consumption of omega-3, and were able to produce the supplement to the 
nurse interviewer for verification.  
 
2.4 Covariables  
 Related data collected at baseline included age (in years), gender, education level, 
cigarette smoking (current smokers versus past-smokers or non-smokers), and alcohol 
drinking (at least 1 alcoholic drink daily or less). Leisure-time activity was assessed by 
questions on the number and frequency of the respondents’ usual participation in 16 
different categories of physical, social or productive activities, which are commonly 
performed by local older adults during their leisure times (Niti et al., 2008). Participants at 
nutritional risk were identified using the 10-item NSI-DETERMINE (Posner et al., 1993; Yap et 
al., 2004). Chronic medical conditions included  hypertension, diabetes, cardiac diseases, 
stroke, asthma, chronic obstructive pulmonary disease (COPD), major eye disorders 
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(cataract, glaucoma, etc), arthritis, thyroid and gastric problems. Comorbidity was classified 
by the total number of the above chronic conditions for each participant.   The presence of 
vascular risk factors/diseases was defined as any of the following conditions:  hypertension, 
diabetes, cardiac diseases, and stroke. 
  
 The presence of depressive symptoms in the past week was determined using the 
locally validated Chinese version (Nyunt et al., 2009) of the 15-item Geriatric Depression 
Scale (GDS) (Yesavage, 1988). Apolipoprotein E (APOE) genotyping was identified by 
polymerase chain reaction (PCR) amplification followed by restriction endonuclease 
digestion of the PCR product (PCR-RFLP). 
 
2.5 Statistical analysis 
 Independent t-test and Chi-squared trend tests were used for continuous and 
categorical variables respectively. Multivariate analyses of the associations between n3-
PUFA supplement intake and cognitive decline were performed using binomial logistic 
regression models controlling for relevant confounders. The covariables included age (single 
years), education (0-6 years or more), gender, number of medical comorbidities (none, 1-2, 
3+), presence of vascular risk factors/ diseases, depressive symptoms (GDS≥5 or less), level 
of leisure-time activities (low, <8; medium, 8-11; high, ≥12), smoking, alcohol drinking, 
nutritional status (NSI ≥5 or less), APOE status, length of follow-up and baseline MMSE 
score.  
 
 To reduce reporting bias due to impaired cognitive functioning, we re-analyzed the 
data after excluding participants with MMSE score <24 at baseline to examine whether n3-
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PUFA supplement intake remained associated with cognitive decline. Because of the 
increased probability that persons with a history of cardiometabolic diseases (coronary 
heart diseases, cardiac failure, stroke, and diabetes) might alter their habitual consumption 
of omega-3 supplement, we also reanalyzed the relationship after excluding these 
participants in the analysis. ORs of associations were computed yielding point estimates 
with 95% confidence intervals (95% C.I.). A 2-sided p value of less than 0.05 was considered 
significant. All analyses were carried out with SPSS statistical software version 15.0 (SPSS, 
Inc., Chicago, Illinois).  
 
3. Results 
 In the sample, 90 (6%) of the participants reported daily consumption of n-3 PUFA 
supplement (Table 1). Compared to those who did not consume n-3 PUFA supplement daily, 
those with daily n-3 PUFA supplement consumption were younger (p=0.029), had more 
years of education (p<0.001), higher level of leisure-time activities (p=0.006), and shorter 
lengths of follow-up (p=0.011), but otherwise did not differ significantly in gender, number 
of medical comorbidities, presence of vascular risk factors/diseases, APOE status, smoking, 
alcohol drinking, or number of depressive symptoms. Of note, there were no significant 
differences in nutritional status or frequency of fish intake. Daily n-3 PUFA supplement 
consumers compared to non-daily consumers showed higher mean MMSE scores at 
baseline (mean 28.2 versus 27.0, p<0.001), fewer cases of cognitive impairment (4.4% 




 The OR estimated in univariate analysis for the association of daily intake of n-3 
PUFA supplement with cognitive decline was 0.38 (95% CI 0.16-0.88) (Table 2). In 
multivariate analyses, the estimated OR remained significantly low (OR=0.37, 95% C.I. 0.16-
0.87), after controlling for age, gender, education, number of medical illness, the presence 
of vascular risk factors/diseases, smoking, alcohol drinking, depression, APOE status, 
nutritional status, level of leisure activity, baseline MMSE and length of follow-up together, 
and after excluding participants with cognitive impairment (MMSE<24) at baseline 
(OR=0.36, 95% C.I. 0.15-0.85), and after further excluding those with diabetes, stroke, and 
cardiac diseases (OR=0.23, 95% C.I. 0.07-0.75). We found no statistically significant 




 These results based on a large population study of community-living older Chinese 
persons aged 55 years and above suggest that daily n-3 PUFA supplements intake is 
independently associated with lower risk of cognitive decline. The finding is consistent with 
previous observational studies based on dietary intake of n-3 PUFA (either from fish and/or 
other food items). 
 
 The longitudinal population-based design and large sample size are the strengths of 
the present study. However, there are some limitations. First, the selection bias due to 
death (N=45) and lost-to-follow-up (N=889) could possibly influence the results.  
Participants who were not assessed at follow-up had lower baseline cognitive test scores 
(p=0.003) and more depressive symptoms (p=0.004) than participants who were followed 
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up. However, there was no significant difference in age (p=0.73), education level (p=0.67) 
and the proportion of those taking daily n-3 PUFA supplements (p=0.86).  Second, although 
we adjusted for many possible confounding variables, residual confounding by unmeasured 
variables remains a possibility.  These unmeasured confounders could arise from the 
possibility that n-3 PUFA supplements consumers might have healthier lifestyles. Third, our 
measures of dietary intake of n-3 PUFA was limited to only fish consumption, which may 
vary in n-3 PUFA content depending on the types of fish and preparations, and hence may 
not correlate well with the actual total amounts of n-3 PUFA intake. Deep sea fatty fish 
which are more abundant in n-3 PUFA is less commonly consumed in the local population 
and this may explain the lack of significant association observed for fish consumption. More 
objective and accurate measures for assessing n-3 PUFA intake should use serum or red 
blood cell membranes levels of n-3 2UFA (Adamson et al., 2009). 
 
 To our knowledge, no previous observational study has investigated and reported a 
reduced risk of cognitive decline associated with the use of n3-PUFA supplements in non-
demented individuals. To date, all clinical trials which evaluated the use of n-3 PUFA 
supplements have failed to provide conclusive evidence that they slow cognitive decline in 
Alzheimer’s disease patients. However, in a trial which included 174 subjects with mild to 
moderate AD, a reduction in cognitive decline was observed in a small subgroup of 
dementia patients with the mildest cognitive impairment (Freund-levi et al., 2006).  
 
 Factors such as education, levels of leisure time activities, and cardiovascular factors 
have been shown in this study population and other studies (Ng et al., 2007; Niti et al., 2008; 
Ho et al., 2008) to strongly influence the likelihood of cognitive decline, and were possible 
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confounders in this study. Daily n-3 PUFA supplements consumers were younger, better 
educated and engaged more frequently in leisure time activities, and had better cognitive 
function at baseline. Multivariate analyses that controlled for these confounding variables 
demonstrated an independent inverse association between n3-PUFA supplement intake and 
cognitive decline.  
 
 There was the possibility of the results being biased by the inclusion of individuals 
with cognitive impairment at baseline, since they could have changed their n-3 PUFA intake 
or might give imprecise information about their actual food consumption. To reduce this 
reporting bias, we excluded participants with MMSE score<24 at baseline and found that n-3 
PUFA supplements intake remained negatively associated with cognitive decline.  
Similarly, because persons with cardiac diseases, stroke and diabetes are also at increased 
risk of dementia and cognitive decline, and may also alter their habitual food intake 
including omega-3 supplement, we also re-estimated the OR after eliminating these 
individuals and found that the association remained significant. Finally, we found no 
significant differences in nutritional status or frequency of fish intake between daily 
consumers and non-consumers of n-3 PUFA supplements.     
             
 In conclusion, the data in this observational study supports the suggestion that daily 
consumption of omega-3 polyunsaturated fatty acid supplements may be beneficial in 
preventing cognitive decline in individuals without dementia. However, data from more 
prospective and interventional studies should provide firmer evidence to support the use of 
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Baseline characteristics of study participants  
 
Daily Omega-3 PUFA intake 
pa –Value 
No (N=1385) Yes (N=90) 
    
Length of follow-up, yr (mean/ SD) 1.58 (0.50) 1.45 (0.42) 0.011 
Age, yr (mean/ SD) 66.2 (7.5) 64.4 (6.6) 0.029 
Female 65.8% 64.4% 0.80 
Education: 6 yrs or less 55.1% 28.9% <0.001 
Number of medical illness    
   None 8.7% 7.8% 
0.91    1-2 49.0% 51.1% 
   3+ 42.4% 41.1% 
Vascular risk factors/ diseases    
Hypertension 55.6% 54.4% 0.83 
Diabetes 17.0% 10.0% 0.085 
Cardiac diseasesb 7.6% 8.9% 0.65 
Stroke 3.8% 4.4% 0.74 
APOE-ε4 carrier 18.2% 19.1% 0.83 
Current smoker 5.6% 5.6% 0.99 
Alcohol drinking 7.5% 7.8% 0.93 
Level of leisure-time activities    
   Low (score <8) 34.0% 17.8% 
0.006    Moderate (score 8-11) 35.6% 43.3% 
   High (score >11) 30.4% 38.9% 
Nutritional risk (Nutrition Screening score ≥3) 30.8% 33.3% 0.62 
Fish consumption (>3 times a week) 49.3% 47.8% 0.78 
Depression (GDS≥5) 11.8% 14.4% 0.45 
MMSE score (mean/ SD) 27.0 (3.4) 28.2 (2.4) <0.001 
Cognitive impairment at baseline 11.7% 4.4% 0.035 
Cognitive decline at follow-up 15.9% 6.7% 0.019 
    
a Independent sample t test for continuous variables, chi-square test for categorical 
variables 
b Ischaemic heart disease or congestive heart failure or atrial fibrillation 
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Table 2    
Associations between daily intake of omega-3 PUFA supplement and cognitive declinea  
Logistic Regression Model OR [95% CI]b p-Value 
   
Unadjusted 0.38 (0.16-0.88) 0.023 
Adjusted c 0.37 (0.16-0.87) 0.024 
Excluding respondents with cognitive impairment (MMSE<24) at baseline c 0.36 (0.15-0.85) 0.020 
Excluding respondents with cognitive impairment, diabetes, stroke, and cardiac diseases c  0.23 (0.07-0.75) 0.015 
  
a  Cognitive decline: a minimum of 2-point drop in MMSE during follow-up period 
b Odds Ratio and 95% Confidence Interval OR [95%CI] 
c Adjusted for: age, gender, education, number of medical comorbidity, the presence of vascular risk factors/diseases, smoking, 
alcohol drinking, depression, APOE status (ε4 allele carriers vs. non-carriers), nutritional status, level of leisure activities, baseline 
MMSE and length of follow-up  
 
 
 
 
 
